AMN Healthcare Services, Inc. AMN is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), favorable healthcare staffing demand, diversified workforce solutions, and investments in technology and AI-driven platforms. However, stiff competition, industry regulations and changing marketplace conditions are major downsides.
Shares of this Zacks Rank #3 (Hold) company have skyrocketed 114.5% year to date against the industry's 12% decline. However, the S&P 500 Index has risen 12.2% in the said timeframe.
This renowned player in the healthcare total talent services space has a market capitalization of $1.31 billion. The company projects 144.1% year-over-year earnings growth for 2026 and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 96.63%.
Image Source: Zacks Investment Research
Factors Favoring AMN Stock
Favorable Healthcare Staffing Demand: Demand for healthcare staffing remains supported by population growth, aging demographics, increasing care complexity and persistent labor shortages. Healthcare providers are increasingly using flexible workforce models and external staffing partners to manage labor variability and improve efficiency.
In second-quarter 2026, travel nurse volume increased 6% year over year, while allied volume rose 7%, the strongest growth rates in four years. Travel nurse orders turned positive in May and reached approximately 40% growth by early August, while allied orders grew in the mid-teens during June and July. Management expects more than 10% year-over-year growth in both businesses in the third quarter and forecasts Nurse and Allied Solutions revenue growth of 9-11%. Sustained demand could drive stronger staffing volumes and support AMN’s revenue recovery.
Expanding MSP Penetration: AMN Healthcare’s Managed Services Programs (MSPs) strengthen client relationships by helping providers manage supplemental labor across AMN and third-party suppliers. MSP arrangements accounted for approximately 46% of consolidated revenues in second-quarter 2026. In 2025, AMN managed $1.8 billion of spend through MSPs and $3.3 billion, including vendor-neutral programs. Broad-based demand across regions, provider sizes and service models further supports the platform’s workforce optimization capabilities. The scale of AMN’s MSP platform provides recurring access to large healthcare staffing demand and strengthens client retention while creating opportunities to capture additional market share.
Diversified Workforce Solutions: AMN has expanded beyond traditional staffing into technology-enabled total talent solutions spanning staffing, recruitment, MSP, Vendor Management Systems (VMS), language services, consulting and workforce optimization. Second-quarter growth included travel nurse, allied and international nurse staffing, while physician search increased new searches 40% year over year and executive search rose 30%.
AMN also expanded its WorkWise platform with supplier and rate intelligence, while Passport users surpassed 400,000. In June 2026, the company acquired Jaide Health to enhance AI-enabled language interpretation and ESSENTIAL Leadership Assessment to expand leadership evaluation, coaching and succession planning capabilities. This broad service portfolio creates multiple avenues for growth beyond traditional healthcare staffing.
Downsides of AMN Stock
Stiff Competition: AMN Healthcare operates in a highly competitive staffing and workforce-solutions market, with pressure from national, regional and specialized providers. Locum tenens demand is increasingly shifting toward vendor-neutral channels, which management describes as highly competitive. Language services revenues also declined as pricing per minute fell 8%, while Technology and Workforce Solutions revenues dropped 15% year over year. Continued competition could limit pricing power, fill rates and revenue growth.
Changing Marketplace Conditions: Healthcare providers continue to adjust staffing models and focus on controlling labor costs. Contingent labor premiums have fallen to the mid- to high-single digits from the mid- to high-teens before COVID-19, indicating a normalization of pandemic-era economics. Although Nurse and Allied demand is recovering, third-quarter 2026 consolidated revenue guidance calls for only 1-3% year-over-year growth as declines in other segments offset staffing gains. These market shifts could slow AMN’s overall recovery.
Healthcare Industry Regulations: Regulatory and administrative changes can affect clinician availability, client demand and international staffing. AMN’s international nurse business benefited from forward movement in visa cutoff dates, but embassy appointment backlogs remain a constraint. Management indicated that resolving these delays will influence international growth in 2027. Changes in immigration policies or continued processing delays could therefore create staffing shortages, delay placements and increase operating uncertainty.
AMN Healthcare Services Inc Price
AMN Healthcare Services Inc price | AMN Healthcare Services Inc Quote
Estimate Trend
AMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 22.9% to $3.32.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $648 million and 22 cents, respectively, suggesting 2.1% growth and a 43.6% decline from the year-ago reported numbers.
Key Picks
Some better-ranked stocks from the broader medical space are Veracyte VCYT, Globus Medical GMED and West Pharmaceutical WST.
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMN Healthcare Services Inc (AMN): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).